In the last trading session, 1.53 million Larimar Therapeutics Inc (NASDAQ:LRMR) shares changed hands as the company’s beta touched 0.96. With the company’s per share price at $3.67 changed hands at $0.12 or 3.38% during last session, the market valuation stood at $234.17M. LRMR’s last price was a discount, traded about -272.75% off its 52-week high of $13.68. The share price had its 52-week low at $3.01, which suggests the last value was 17.98% up since then. When we look at Larimar Therapeutics Inc’s average trading volume, we note the 10-day average is 0.67 million shares, with the 3-month average coming to 835.29K.
Analysts gave the Larimar Therapeutics Inc (LRMR) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.08. If we narrow down to specifics, the data shows that 0 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended LRMR as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight. Larimar Therapeutics Inc’s EPS for the current quarter is expected to be -0.32.
Larimar Therapeutics Inc (NASDAQ:LRMR) trade information
Instantly LRMR was in green as seen at the end of in last trading. With action 5.46%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -5.17%, with the 5-day performance at 5.46% in the green. However, in the 30-day time frame, Larimar Therapeutics Inc (NASDAQ:LRMR) is -8.48% down. Looking at the short shares, we see there were 5.24 million shares sold at short interest cover period of 4.95 days.
The consensus price target for the stock as assigned by Wall Street analysts is 15, meaning bulls need an upside of 75.53% from its current market value. According to analyst projections, LRMR’s forecast low is 14 with 22 as the target high. To hit the forecast high, the stock’s price needs a -499.46% plunge from its current level, while the stock would need to soar -281.47% for it to hit the projected low.
Larimar Therapeutics Inc (LRMR) estimates and forecasts
Data shows that the Larimar Therapeutics Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -54.12% over the past 6 months, a -36.90% in annual growth rate that is considerably lower than the industry average of 17.30%.
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 48.33%. The 2025 estimates are for Larimar Therapeutics Inc earnings to decrease by -43.91%.
LRMR Dividends
Larimar Therapeutics Inc is expected to release its next quarterly earnings report in March.
Larimar Therapeutics Inc (NASDAQ:LRMR)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 1.72% of Larimar Therapeutics Inc shares while 107.93% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 109.81%. There are 107.93% institutions holding the Larimar Therapeutics Inc stock share, with DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) the top institutional holder. As of 2024-06-30, the company held 39.6461% of the shares, roughly 21.23 million LRMR shares worth $153.93 million.
RA CAPITAL MANAGEMENT, L.P. holds the second largest percentage of outstanding shares, with 11.2884% or 6.05 million shares worth $43.83 million as of 2024-06-30.
Among Mutual Funds, the top two as of Sep 30, 2024 were Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF. With 1.34 shares estimated at $4.92 million under it, the former controlled 2.10% of total outstanding shares. On the other hand, iShares Russell 2000 ETF held about 1.86% of the shares, roughly 1.19 shares worth around $4.36 million.
